Literature DB >> 27864628

Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.

Kea Turner1, Cleo A Samuel2,3, Heidi As Donovan4, Ellen Beckjord5, Alexandra Cardy5, Mary Amanda Dew6, G J van Londen7.   

Abstract

PURPOSE: Providers' communication skills play a key role in encouraging breast cancer survivors to report symptoms and adhere to long-term treatments such as adjuvant endocrine therapy (AET). The purpose of this study was to examine provider perspectives on patient-provider communication regarding AET symptom management and to explore whether provider perspectives vary across the multi-disciplinary team of providers involved in survivorship care.
METHODS: We conducted three one-hour focus groups with a multi-disciplinary group of health care providers including oncology specialists, primary care physicians, and non-physician providers experienced in caring for breast cancer survivors undergoing AET (n = 13). Themes were organized using Epstein and Street's (2007) Framework for Patient-Centered Communication in Cancer Care.
RESULTS: The findings of this study suggest providers' communication behaviors including managing survivors' uncertainty, responding to survivors' emotions, exchanging information, and enabling self-management influences the quality of patient-provider communication about AET symptoms. Additionally, lack of systematic symptom assessment tools for AET requires providers to use discretion in determining which symptoms to discuss with survivors resulting in approaches that vary based on providers' discipline.
CONCLUSION: There may be AET-specific provider communication skills and behaviors that promote effective patient-provider communication but additional research is needed to identify practices and policies that encourage these skills and behaviors among the many providers involved in survivorship care. Efforts are also needed to coordinate AET symptom assessment across providers, clarify providers' roles in symptom assessment, and determine best practices for AET symptom communication.

Entities:  

Keywords:  Adjuvant endocrine therapy; Aromatase inhibitors; Breast cancer; Patient-centered communication; Patient-provider communication; Symptom management

Mesh:

Substances:

Year:  2016        PMID: 27864628      PMCID: PMC5363398          DOI: 10.1007/s00520-016-3491-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  37 in total

1.  Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

Authors:  Harold J Burstein; Sarah Temin; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Diana Rowden; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

2.  Seasons of survival: reflections of a physician with cancer.

Authors:  F Mullan
Journal:  N Engl J Med       Date:  1985-07-25       Impact factor: 91.245

3.  Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.

Authors:  C L Loprinzi; J W Kugler; J A Sloan; J A Mailliard; B I LaVasseur; D L Barton; P J Novotny; S R Dakhil; K Rodger; T A Rummans; B J Christensen
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

4.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

5.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.

Authors:  R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

Review 6.  Problems to discuss with cancer patients in palliative care: a comprehensive approach.

Authors:  Bart H P Osse; Myrra J F J Vernooij-Dassen; Egbert Schadé; Berna de Vree; Maria E T C van den Muijsenbergh; Richard P T M Grol
Journal:  Patient Educ Couns       Date:  2002-07

7.  Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study.

Authors:  Thomas Ruhstaller; Roger von Moos; Kaspar Rufibach; Karin Ribi; Agnes Glaus; Bruno Spaeti; Dieter Koeberle; Urs Mueller; Markus Hoefliger; Dagmar Hess; Christel Boehme; Beat Thuerlimann
Journal:  Oncology       Date:  2009-01-22       Impact factor: 2.935

8.  Measure once, cut twice--adding patient-reported outcome measures to the electronic health record for comparative effectiveness research.

Authors:  Albert W Wu; Hadi Kharrazi; L Ebony Boulware; Claire F Snyder
Journal:  J Clin Epidemiol       Date:  2013-08       Impact factor: 6.437

9.  Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.

Authors:  Katherine D Crew; Jillian L Capodice; Heather Greenlee; Lois Brafman; Deborah Fuentes; Danielle Awad; Wei Yann Tsai; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.

Authors:  C McCowan; J Shearer; P T Donnan; J A Dewar; M Crilly; A M Thompson; T P Fahey
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more
  4 in total

1.  Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.

Authors:  Cleo A Samuel; Kea Turner; Heidi A S Donovan; Ellen Beckjord; Alexandra Cardy; Mary Amanda Dew; G J van Londen
Journal:  Support Care Cancer       Date:  2017-07-06       Impact factor: 3.603

2.  Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.

Authors:  Vanessa B Sheppard; Arnethea L Sutton; Alejandra Hurtado-de-Mendoza; Jun He; Bassam Dahman; Megan C Edmonds; Mary Helen Hackney; Mahlet G Tadesse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-01-29       Impact factor: 4.254

3.  Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.

Authors:  Leah K Lambert; Lynda G Balneaves; A Fuchsia Howard; Stephen L K Chia; Carolyn C Gotay
Journal:  Curr Oncol       Date:  2021-04-09       Impact factor: 3.677

4.  THRIVE intervention development: using participatory action research principles to guide a mHealth app-based intervention to improve oncology care.

Authors:  Janeane N Anderson; Rebecca A Krukowski; Andrew J Paladino; J Carolyn Graff; Lee Schwartzberg; Andrea N Curry; Gregory A Vidal; Tameka N Jones; Teresa M Waters; Ilana Graetz
Journal:  J Hosp Manag Health Policy       Date:  2021-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.